IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo

Annals of the New York Academy of Sciences

Volumn 795, Issue , 1996, Pages 284-293

  Zitvogel, Laurence ^a   Couderc, Bettina ^a   Mayordomo, Jose I ^a   Robbins, Paul D ^a   Lotze, Michael T ^a   Storkus, Walter J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 12; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; CELLULAR IMMUNITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; GENETIC ENGINEERING; GENETIC TRANSFECTION; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA; MOUSE; NONHUMAN; PLASMID; VACCINATION;

EID: 0030463415     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb52678.x     Document Type: Conference Paper

References (18)

1. KOBAYASHI, M., L. FITZ, M. RYAN, R. M. HEWICK, S. C. CLARK, S. CHAN, R. LOUDON, F. SHERMAN, B. PERUSSIA & G. TRINCHIERI. 1989. Identification and purification of NKSF, a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170: 827-845.
2. STERN, A. S., F. J. PODLASKI, J. D. HULMES, Y. C. E. PAN, P. M. QUINN, A. G. WOLITZKY, P. C. FAMILLETTI, D. L. STREMLO, T. TRUITT, R. CHIZZONITE & M. K. GATELY. 1990. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 87: 6808-6812.
3. AFONSO, L. C., T. M. SCHARTON, L. Q. VIEIRA, M. WYSOCKA, G. TRINCHIERI & P. SCOTT. 1994. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263: 235-237.
4. NOGUCHI, Y., E. C. RICHARDS, Y-T. CIIEN & L. J. OLD. 1995. Influence of IL-12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92: 2219-2223.
5. PARDOLL, D. M. 1995. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13: 399-415.
6. SHU, U., M. KINIWA, C. You Wu, C. MALISZEWSKI, N. VEZZIO, J. HAKIMI, M. GATELY & G. DELESPESSE. 1995. Activated T cells induce IL-12 production by monocytes via CD40-CD40L interaction. Eur. J. Immunol. 25: 1125-1128.
7. + T cells. J. Immunol. 154: 5071-5079.
8. + T cells requires the coordinate action of IL-12 and IFNrand is inhibited by TGF-β. Eur. J. Immunol. 24: 793-798.
9. ZITVOGEL, L., J. I. MAYORDOMO, T. TJANDRAWAN, A. B. DELEO, M. R. CLARKE, M. T. LOTZE & W. J. STORKUS. 1996. Therapy of murine tumors with tumor peptide pulsed dendritic cells: Dependence on T-cells, B7 costimulation, and Thl-associated cytokines. J. Exp. Med. 183: 87-98.
10. MAYORDOMO, J. I., T. ZORINA, W. J. STORKUS, C. CELLUZZI, L. D. FALO, C. J. MELIEF, S. T. ILDSTAD, W. M. KAST, A. B. DELEO & M. T. LOTZE. 1995. Bone-marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity. Nature Med. 1: 1297-1302.
11. MAYORDOMO, J. I., L. ZITVOGEL, T. TJANDRAWAN, M. T. LOTZE & W. J. STORKUS. 1996. Dendritic cells presenting tumor peptide epitopes stimulate effective anti-tumor CTL in vitro and in vivo. Proc. Int. Assoc. Immunol. In press.
12. TAMARA, H. T., H. J. ZEH III, W. J. STORKUS, I. PAPPO, S. C. WATKINS, U. GUBLER, S. F. WOLF, P. D. ROBBINS & M. T. LOTZE. 1994. Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce anti-tumor immunity to a murine melanoma in vivo. Cancer Res. 54: 182-189.
13. SUN, W. H., J. K. BURKHOLDER, J. SUN, J. GULP, J. TURNER, X. G. LU, T. D. PUGH, W. B. ERSHLER & N. S. YANG. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc. Nail. Acad. Sci. USA 92: 2889-2893.
14. HUANG, A. Y. C., P. GOLUMBECK, M. AHMADZADEH, E. JAFFEE, D. M. PARDOLL & H. LEVITSKY. 1994. The role of bone marrow-derived cells in presenting class I-restricted tumor antigens. Science 264: 961-965.
15. PORGADOR, A. & E. GILBOA. 1995. Bone-marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182: 255-260.
16. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived-peptide-pulsed dendritic cells. Intl. Immunol. 5: 849-857.
17. FLAMAND, V., T. SORNASSE, K. THIELEMANS, C. DEMANET, M. BAKKUS, H. BAZIN, F. THIELEMANS, O. LEO, J. URBAIN & M. MOSER. 1994. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur. J. Immunol. 24: 605-610.
18. CELLUZZI, C., J. I. MAYORDOMO, W. J. STORKUS, M. T. LOTZE & L. D. FALO. 1996. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J. Exp. Med. 183: 283-288.